Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mika Sunakawa

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancers|December 18, 2019
Immunotherapy for Multiple MyelomaHideto Tamura, Mariko Ishibashi, Mika Sunakawa, et al.
Cancers|April 16, 2020
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple MyelomaHideto Tamura, Mariko Ishibashi, Mika Sunakawa-Kii, et al.
Molecular Cancer Therapeutics|April 21, 2021
Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma CellsMariko Ishibashi, Junichi Yamamoto, Takumi Ito, et al.
Experimental Hematology|August 21, 2020
The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myelomaMariko Ishibashi, Mika Sunakawa-Kii, Yuta Kaito, et al.
Cancer Immunology Research|July 22, 2016
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1Mariko Ishibashi, Hideto Tamura, Mika Sunakawa, et al.
Experimental Hematology|February 16, 2023
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myelomaRyosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, et al.
Cell Death and Differentiation|August 23, 2024
Gelsolin alleviates rheumatoid arthritis by negatively regulating NLRP3 inflammasome activationJiyeon Lee, Fumiyuki Sasaki, Eri Koike, et al.
Oncotarget|November 10, 2018
Clinical impact of serum soluble SLAMF7 in multiple myelomaMariko Ishibashi, Saori Soeda, Makoto Sasaki, et al.
Molecular Cancer Research : MCR|January 25, 2020
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple MyelomaMariko Ishibashi, Risa Takahashi, Asako Tsubota, et al.
Asia-Pacific Journal of Clinical Oncology|May 23, 2022
Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative studyShunsuke Yui, Satoshi Wakita, Yasunobu Nagata, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancers|December 18, 2019
Immunotherapy for Multiple MyelomaHideto Tamura, Mariko Ishibashi, Mika Sunakawa, et al.
Cancers|April 16, 2020
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple MyelomaHideto Tamura, Mariko Ishibashi, Mika Sunakawa-Kii, et al.
Molecular Cancer Therapeutics|April 21, 2021
Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma CellsMariko Ishibashi, Junichi Yamamoto, Takumi Ito, et al.
Experimental Hematology|August 21, 2020
The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myelomaMariko Ishibashi, Mika Sunakawa-Kii, Yuta Kaito, et al.
Cancer Immunology Research|July 22, 2016
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1Mariko Ishibashi, Hideto Tamura, Mika Sunakawa, et al.
Experimental Hematology|February 16, 2023
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myelomaRyosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, et al.
Cell Death and Differentiation|August 23, 2024
Gelsolin alleviates rheumatoid arthritis by negatively regulating NLRP3 inflammasome activationJiyeon Lee, Fumiyuki Sasaki, Eri Koike, et al.
Oncotarget|November 10, 2018
Clinical impact of serum soluble SLAMF7 in multiple myelomaMariko Ishibashi, Saori Soeda, Makoto Sasaki, et al.
Molecular Cancer Research : MCR|January 25, 2020
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple MyelomaMariko Ishibashi, Risa Takahashi, Asako Tsubota, et al.
Asia-Pacific Journal of Clinical Oncology|May 23, 2022
Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative studyShunsuke Yui, Satoshi Wakita, Yasunobu Nagata, et al.
Pageof 1